Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | TTI-621 |
Trade Name | |
Synonyms | SIRPalpha-Fc|TTI621|TTI 621|Ontorpacept |
Drug Descriptions |
TTI-621 (Ontorpacept) is a fusion, consisting of SIRPa fused to the human IgG1 Fc region, that binds to CD47 and blocks inhibitory signaling to macrophages, resulting in increased phagocytosis of tumor cells (PMID: 27856600, PMID: 28286286) may also stimulate cytotoxic T-cells (PMID: 29873856). |
DrugClasses | CD47 Antibody 31 Immune Checkpoint Inhibitor 149 |
CAS Registry Number | 2131089-46-6 |
NCIT ID | C125718 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Daratumumab + TTI-621 | Daratumumab TTI-621 | 0 | 1 |
Doxorubicin + TTI-621 | Doxorubicin TTI-621 | 0 | 1 |
Pembrolizumab + TTI-621 | Pembrolizumab TTI-621 | 0 | 1 |
TTI-621 | TTI-621 | 0 | 2 |